New drug combination with immunotherapy for liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called CVM-1118 combined with an immunotherapy drug (sintilimab) and a procedure called TACE (a catheter-based treatment that delivers medicine directly to tumors) in people with hepatocellular carcinoma (liver cancer) that cannot be cured by surgery. The goal is to see if this combination is effective and safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with hepatocellular carcinoma (liver cancer) confirmed by imaging or biopsy
- Your cancer has not spread outside the liver
- Your cancer cannot be treated with curative surgery, transplant, or ablation (heat/cold therapy)
- Your cancer can be treated with TACE and will need no more than 4 TACE procedures total
- Your liver function is in the best category (Child-Pugh Class A) with good blood counts and organ function
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination treatment for liver cancer that cannot be removed by surgery. It combines a procedure called TACE (which delivers chemotherapy directly to the tumor) with an investigational drug, ivonescimab, which helps the immune system fight cancer. The goal is to see if this combination is safe and effective for people whose cancer has not spread beyond the liver.
This study tests a new approach: giving two immunotherapy drugs (sintilimab and ipilimumab) along with treatments that block blood flow to the tumor (TACE or ablation) before surgery for liver cancer that is at high risk of coming back. The goal is to see if this combination can shrink the tumor and reduce the chance of recurrence after surgery.
This trial tests whether combining an immunotherapy drug (sintilimab) with a targeted therapy (lenvatinib) after surgical removal of liver cancer can help prevent the cancer from coming back. It is for patients whose tumors show a specific blood vessel pattern called VETC.
This trial tests a combination of immunotherapy (sintilimab), a targeted anti-angiogenic drug (bevacizumab biosimilar), and liver-directed therapies (TACE-HAIC) before and after surgery for hepatocellular carcinoma that has spread to the portal vein. The goal is to see if this approach improves outcomes for patients with advanced but resectable liver cancer.
This trial tests a combination of liver-directed chemotherapy (HAIC), an immunotherapy drug (sintilimab), and a drug that blocks blood vessel growth (bevacizumab biosimilar) for advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this triple therapy can shrink or control the cancer.
This trial tests whether adding a liver-directed treatment to standard systemic therapy can improve outcomes for people with liver cancer that cannot be removed. It may help shrink tumors or slow the disease while on current treatment.
Hear when a new HCC - Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.